AnaptysBio to Present at the Jefferies 2019 Healthcare Conference
May 28 2019 - 6:55AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today announced
that Hamza Suria, chief executive officer of AnaptysBio, will
present at the Jefferies 2019 Healthcare Conference on Friday, June
7, 2019, at 9:30 a.m. ET in New York City.
A webcast of the presentation will be available through the
investor section of the AnaptysBio website. A replay of the webcast
will be available for 90 days following the event.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
Company’s proprietary anti-inflammatory pipeline includes its
anti-IL-33 antibody etokimab, previously referred to as ANB020, for
the treatment of moderate-to-severe atopic dermatitis, eosinophilic
asthma, and adult chronic rhinosinusitis with nasal polyps, or
CRSwNP; its anti-IL-36R antibody ANB019 for the treatment of rare
inflammatory diseases, including generalized pustular psoriasis, or
GPP, and palmoplantar pustulosis, or PPP; and novel
anti-inflammatory checkpoint receptor modulator antibodies for
treatment of certain autoimmune diseases where immune checkpoint
receptors are insufficiently activated. AnaptysBio’s antibody
pipeline has been developed using its proprietary somatic
hypermutation, or SHM, platform, which uses in vitro SHM for
antibody discovery and is designed to replicate key features of the
human immune system to overcome the limitations of competing
antibody discovery technologies. AnaptysBio has also developed
multiple therapeutic antibodies in an immuno-oncology partnership
with TESARO (recently acquired by GlaxoSmithKline), including an
anti-PD-1 antagonist antibody (dostarlimab (TSR-042)), an
anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3
antagonist antibody (TSR-033), and an inflammation partnership with
Celgene, including an anti-PD-1 checkpoint agonist antibody
(CC-90006) currently in clinical development.
Contact:Dominic Piscitelli
AnapytsBio,
Inc.858.362.6348dpiscitelli@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024